Malvern-based Ocugen, a biotechnology company pioneering gene therapies for blindness diseases, recently appointed Rita Johnson-Greene as chief financial officer.
“Mrs. Johnson-Greene’s diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen’s CFO,” Dr. Shankar Musunuri, Ocugen chairman, CEO and co-founder, said. “We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications this year.”
Mrs. Johnson-Greene has more than 20 years of healthcare experience. She comes to Ocugen from the Alliance for Regenerative Medicine where she served as chief operating officer and was tasked with leading operations, finance, and global expansion initiatives.
She also was Genetix Biotherapeutics vice president of sales and qualified treatment centers and held senior leadership positions at Spark Therapeutics. Earlier in her career, Johnson-Greene was a strategic consultant with Accenture’s strategy practice and held roles in finance, commercial operations, and sales for AstraZeneca.
Johnson-Greene also serves on the Drexel University Biomed Dean’s Executive Advisory Council and is a guest lecturer.
Ocugen has programs in development for inherited retinal diseases and blindness diseases including retinitis pigmentosa, Stargardt disease, and geographic atrophy.